Juul Faces Market Withdrawal in the US: Implications and Controversies

Jul.08.2022
Juul Faces Market Withdrawal in the US: Implications and Controversies
The FDA ordered Juul products to be removed from the US market due to concerns over youth vaping.

On June 23, the US Food and Drug Administration (FDA) announced that all Juul products must be removed from the US market. This decision significantly expanded the existing ban on the company's nicotine e-cigarettes among teenagers to include adults as well. The following day, Juul appealed to the federal court to temporarily halt the ban and questioned the decision. The court agreed to temporarily suspend the ban, and currently, Juul products are still being sold in the US.


Lynn Kozlowski, a professor at the State University of New York at Buffalo's School of Public Health and Health Professions, has been researching nicotine and tobacco addiction for several decades. In this Q&A, he addresses the recent controversy surrounding Juul products and how they fit into broader discussions among adults and young people about e-cigarettes, tobacco use, and public health.


Why does the US Food and Drug Administration want to stop the sale of Juul products?


According to the FDA, the decision to remove certain flavored electronic cigarette products from the market is a preventative measure due to the lack of "sufficient evidence of product toxicology profiles" to ensure public health and safety. The FDA also noted that it has not received any information indicating that Juul products pose an imminent danger.


In a statement, FDA Commissioner Robert M. Califf addressed the impact of Juul products on youth e-cigarette use. This decision comes as some are hoping for new bans on Juul products and other adult e-cigarettes, in effort to decrease teen e-cigarette usage.


How do the health risks of electronic cigarettes compare to traditional smoking?


At least half of smokers die prematurely due to cancer, obstructive lung disease and cardiovascular diseases caused by smoking, which shorten their average lifespan by 10 years.


Currently, there is a lack of long-term epidemiological data on e-cigarettes. However, assessments conducted in the United States and the United Kingdom have concluded that while the harm from e-cigarettes may be much less than that of traditional cigarettes, they still pose some risks. Potential hazards include nicotine addiction and some cardiovascular risks, although it is estimated that these risks are lower than those associated with smoking cigarettes.


Can electronic cigarettes reduce the harm caused by traditional smoking?


I do not encourage anyone to vape if they do not need to. However, if someone smokes and e-cigarettes help them quit completely, they can be a useful tool in reducing smoking and health issues. Quitting smoking is indisputably good for your health. Research shows that if someone quits smoking before the age of 40, they can avoid 90% of their risk of death compared to continuing to smoke. If someone quits smoking before the age of 30, their health risks are almost the same as someone who has never smoked.


The Centers for Disease Control and Prevention states that there is limited evidence to suggest that e-cigarettes aid in smoking cessation. The U.S. Food and Drug Administration has approved some e-cigarettes for sale, noting that they can be a beneficial tool for smokers in significantly reducing their tobacco use or quitting altogether.


Recent research has shown that electronic cigarettes are more effective in aiding smokers to quit than nicotine replacement therapy. The UK National Health Service has approved electronic cigarettes as a recognized form of smoking cessation aid.


Is vaping still popular among teenagers as it was before?


Teen e-cigarette use is on the decline, according to data from the Centers for Disease Control and Prevention. In 2019, 27.5 percent of high school students reported having used e-cigarettes within the past month. That number dropped to 19.6 percent by 2020, and again to 11.3 percent by 2022. Just over a quarter of monthly users, or roughly 3 percent of high schoolers in 2022, reported using e-cigarettes daily.


Some of the reduction may be due to COVID-19, restrictions on young people's access, and government anti-vaping campaigns.


The widespread publicity around the serious respiratory illness caused by e-cigarettes, known as EVALI, is likely to deter many people from using them. However, research has ultimately shown that the illness is primarily caused by illicit THC-containing e-cigarette products sold on the black market.


Will teenagers who vape lead to a higher smoking rate among adolescents?


Although the decrease in teen e-cigarette use is encouraging, an important question worth asking is whether e-cigarettes directly lead to smoking later on.


Parents have valid reasons to be concerned that e-cigarettes may serve as a gateway to smoking. However, research does not necessarily support this strong causal relationship. Despite the recent surge in e-cigarette use across the country, smoking rates have actually decreased.


According to data from a national survey of nearly 40,000 participants in the US over the past few years, researchers have found that less than 1% of those who tried e-cigarettes for the first time became long-term smokers. Compared to those who first tried cigarettes or other tobacco products, people who first tried e-cigarettes were also less likely to become smokers.


Another large-scale study on American youth found that once researchers controlled for general risky behavior, the history of using e-cigarettes was only moderately or insignificantly associated with increased smoking rates.


How do you balance adult usage with teenage safety?


Even though e-cigarettes are not a major factor contributing to youth smoking, the use of e-cigarette products by young people is still a cause for concern, despite the ban on selling e-cigarettes to those under the age of 21 in 2019.


Completely banning products that may be helpful for adult smokers who want to quit is not the only way to reduce young people's access to these services. As an example, a proposal suggests moving the sales of all nicotine and tobacco products to stores that only allow entry for individuals of 21 years or older.


While products like Juul deserve research and regulation, it is important to remember the established deadline for verification and the ease of access for cigarettes - whether it is for adults or the many teenagers who start smoking every year and will become adult smokers. Persuading as many smokers to quit as possible will save lives.


This article contains excerpts or reprints from third-party sources, and the copyright belongs to the original media and author. If there is any infringement, please contact us for deletion. Any unit or individual who needs to reprint must contact the author, and direct reprinting is prohibited.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

FRE and ALP Push Modern Oral to 48% of Q2 Sales as Turning Point Brands Changes CEO and Lowers Profit-Guidance Ceiling
FRE and ALP Push Modern Oral to 48% of Q2 Sales as Turning Point Brands Changes CEO and Lowers Profit-Guidance Ceiling
Turning Point Brands said Executive Chairman David E. Glazek will become CEO on October 1, replacing Graham Purdy, who is stepping down for personal reasons. The company narrowed its 2026 adjusted EBITDA outlook to $70 million-$80 million from $70 million-$90 million while maintaining Modern Oral gross sales guidance of $330 million-$350 million and net sales guidance of $260 million-$270 million. In the second quarter, Modern Oral net sales rose 128% to $68.4 million and accounted for 48% of company-wide net sales. Adjusted EBITDA fell 50% year over year. TPB shares closed about 10% lower on September 21.
Market
Sep.22 by 2Firsts Perspectives
PMI Pushes Smoke-Free Business in Latin America as Argentina Lifts Heated Tobacco Ban, Mexico City Share Tops 7%
PMI Pushes Smoke-Free Business in Latin America as Argentina Lifts Heated Tobacco Ban, Mexico City Share Tops 7%
Philip Morris International (PMI) showcased IQOS heated tobacco systems and nicotine pouch products at Technovation 2026 in Buenos Aires on October 7–8, presenting research on consumer attitudes, regulatory developments and illicit cigarette trade across Latin America. PMI Chief Global Growth Officer Stefano Volpetti said smoke-free products accounted for more than 7% of the Mexico City market. Argentina repealed its heated tobacco ban in May 2026 and introduced registration requirements for tobacco and nicotine products, while local media reported nicotine pouch sales in Mendoza. A PMI-commissioned survey found that only 8% of respondents across four Latin American countries were familiar with nicotine pouches. A separate KPMG study estimated illicit cigarette consumption at 77 billion sticks across 11 markets in Latin America and Canada in 2025.
PMI
Oct.13
Cochrane 2026 Update Adds Nine Trials, Keeps High-Certainty Finding That Nicotine E-Cigarettes Improve Quit Rates Over NRT
Cochrane 2026 Update Adds Nine Trials, Keeps High-Certainty Finding That Nicotine E-Cigarettes Improve Quit Rates Over NRT
Cochrane’s 2026 update of its living review on electronic cigarettes for smoking cessation included 80 randomized controlled trials involving 29,861 adult smokers, with nine trials added in this update. The review retained its high-certainty conclusion that nicotine e-cigarettes increase smoking cessation rates compared with nicotine replacement therapy. In absolute terms, about 10 in 100 people using nicotine e-cigarettes may quit smoking for at least six months, compared with about 6 in 100 using NRT. The review found no clear difference in serious adverse event rates between the two groups, while longer-term safety and the relative effectiveness of newer device types remain less certain.
Sep.07
2Firsts On-Site | PMI Brings IQOS, ZYN, VEEV and Marlboro Together at Its “Boulevard” at InterTabac 2026
2Firsts On-Site | PMI Brings IQOS, ZYN, VEEV and Marlboro Together at Its “Boulevard” at InterTabac 2026
At InterTabac 2026 in Dortmund, PMI is presenting multiple brands and products along “The PMI Boulevard,” including IQOS, ZYN, VEEV and Marlboro. On-site images captured by 2Firsts show dedicated spaces including the IQOS Boutique, ZYN Café, PMI Gallery and Marlboro Office
Market
Sep.16 by 2Firsts Perspectives
Global Nicotine-Pouch E-Commerce Group Haypp Shuts Sweden’s Snusnetto Over Age Verification as Identity Checks Become Industry Infrastructure for New Nicotine Products
Global Nicotine-Pouch E-Commerce Group Haypp Shuts Sweden’s Snusnetto Over Age Verification as Identity Checks Become Industry Infrastructure for New Nicotine Products
Sweden's Supreme Administrative Court has declined to hear an appeal over age verification for tobacco and nicotine products collected from parcel lockers, leaving in place a lower-court ruling that geo-located BankID verification is insufficient to securely verify the actual recipient. Haypp Group has stopped tobacco and nicotine sales through Snusnetto and is deploying a new system across its other Swedish e-commerce sites to verify the age of the person who actually opens the locker and receives the shipment. The change comes as age verification across next-generation nicotine products expands from purchase checks into retail, delivery and, for some e-cigarettes, device access itself.
Regulations
Oct.20
As JUUL2 Wins FDA Authorization, Harm Reduction Journal Highlights the Role of Real-World Evidence in Nicotine Product Regulation
As JUUL2 Wins FDA Authorization, Harm Reduction Journal Highlights the Role of Real-World Evidence in Nicotine Product Regulation
A commentary published in the international open-access, peer-reviewed Harm Reduction Journal argues that randomized controlled trials remain central to evaluating smoking cessation efficacy but cannot alone capture real-world uptake, complete switching, longer-term use and population impact of non-combustible nicotine products such as e-cigarettes, heated tobacco and nicotine pouches. The authors frame impact as “reach × efficacy” and call for real-world evidence to complement RCTs. Three days after publication, the FDA authorized three JUUL2 products and highlighted complete switching among adult smokers in explaining its decision, providing a timely regulatory backdrop to the debate.
Sep.08